Author:
Kesisoglou Filippos,Wu Yunhui
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. L. Z. Benet, and C. Y. Wu. Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities, NJDMDG, Somerset, NJ, 2006.
2. M. Lindenberg, S. Kopp, and J. B. Dressman. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58:265–278 (2004).
3. N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A. S. Hussain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1:85–96 (2004).
4. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L. X. Yu, and G. L. Amidon. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 3:631–643 (2006).
5. K. C. Johnson, and A. C. Swindell. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13:1795–1798 (1996).
Cited by
122 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献